iRadimed (NASDAQ:IRMD) Releases Q3 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its third quarter 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.540-0.590 for the period, compared to the consensus earnings per share estimate of 0.530. The company issued revenue guidance of $23.0 million-$24.5 million, compared to the consensus revenue estimate of $23.7 million. iRadimed also updated its FY 2026 guidance to 2.090-2.240 EPS.

iRadimed Trading Down 4.6%

IRMD traded down $4.35 during trading on Friday, hitting $90.86. 308,080 shares of the company traded hands, compared to its average volume of 107,190. The stock’s 50-day simple moving average is $94.56 and its two-hundred day simple moving average is $95.73. iRadimed has a 1 year low of $57.83 and a 1 year high of $107.90. The company has a market cap of $1.16 billion, a PE ratio of 49.65 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The firm had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. Equities analysts expect that iRadimed will post 1.52 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $120.00.

Insider Transactions at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the sale, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,250 shares of company stock valued at $1,836,403 in the last ninety days. 34.60% of the stock is owned by company insiders.

Key Stories Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Institutional Investors Weigh In On iRadimed

Several hedge funds and other institutional investors have recently made changes to their positions in IRMD. Quarry LP bought a new stake in shares of iRadimed in the 3rd quarter worth about $40,000. Tower Research Capital LLC TRC grew its holdings in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares during the last quarter. Virtus Advisers LLC bought a new position in iRadimed during the 3rd quarter valued at about $117,000. Aquatic Capital Management LLC raised its position in iRadimed by 210,400.0% in the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock worth $150,000 after purchasing an additional 2,104 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in iRadimed in the 3rd quarter worth about $164,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.